Urs Candrian

Urs Candrian currently serves as the Managing Director at Tapadar Pharma Compliance, where he leverages his extensive expertise in regulatory and quality affairs to guide pharmaceutical companies through complex compliance landscapes. In this leadership role, Urs oversees strategic initiatives aimed at ensuring adherence to global regulatory standards, including GMP, FDA regulations, and international quality systems. His deep understanding of life sciences, biopharmaceuticals, and vaccines positions him as a trusted advisor for organizations navigating clinical development, clinical trials, and licensing processes.

At Tapadar Pharma Compliance, Urs spearheads key projects that focus on optimizing regulatory submissions, enhancing quality management systems, and implementing robust SOPs tailored to the unique needs of each client. His hands-on approach ensures that pharmaceutical businesses maintain compliance with evolving industry standards while accelerating their product development timelines. Urs’s expertise in GMP and clinical development enables him to provide comprehensive support—from early-stage clinical trial design to final product registration—helping clients mitigate risks and achieve regulatory approval efficiently.

Drawing from his previous experience as Director of Regulatory Affairs at Crucell Switzerland AG, Urs brings a wealth of knowledge in managing global license portfolios and navigating the intricacies of international regulatory frameworks. His consultancy work is characterized by a strategic focus on aligning quality systems with industry best practices, fostering a culture of continuous improvement, and ensuring that clients meet stringent regulatory requirements. With a proven track record in the pharmaceutical industry, Urs Candrian remains committed to advancing compliance excellence and supporting innovative healthcare solutions worldwide.